Related references
Note: Only part of the references are listed.A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Ian W. Flinn et al.
EUROPEAN JOURNAL OF CANCER (2016)
Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition
S. Kohrer et al.
LEUKEMIA (2016)
Loss of B-cell Receptor Expression Defines a Subset of Diffuse Large B-cell Lymphoma Characterized by Silent BCR/PI3K/AKT Signaling and a Germinal Center Phenotype Displaying Low-risk Clinicopathologic Features
Wei-Ge Wang et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies
David W. Scott et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H. Wilson et al.
NATURE MEDICINE (2015)
The Genetic Landscape of Diffuse Large B-Cell Lymphoma
Laura Pasqualucci et al.
SEMINARS IN HEMATOLOGY (2015)
B-Cell Receptor Signaling in Diffuse Large B-Cell lymphoma
Ryan M. Young et al.
SEMINARS IN HEMATOLOGY (2015)
Insights into the Molecular Pathogenesis of Activated B-Cell-like Diffuse Large B-Cell Lymphoma and Its Therapeutic Implications
Georg Lenz
CANCERS (2015)
B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas
Shaoying Li et al.
MODERN PATHOLOGY (2015)
Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue
David W. Scott et al.
BLOOD (2014)
MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab
Anamarija M. Perry et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop
James N. Psathas et al.
BLOOD (2013)
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma
Heike Horn et al.
BLOOD (2013)
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
Shimin Hu et al.
BLOOD (2013)
The genetic basis of diffuse large B-cell lymphoma
Laura Pasqualucci
CURRENT OPINION IN HEMATOLOGY (2013)
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
Ranjana H. Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
c-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem Cells
Zuqin Nie et al.
CELL (2012)
Transcriptional Amplification in Tumor Cells with Elevated c-Myc
Charles Y. Lin et al.
CELL (2012)
Quantitative Immunofluorescence Reveals the Signature of Active B-cell Receptor Signaling in Diffuse Large B-cell Lymphoma
Agata M. Bogusz et al.
CLINICAL CANCER RESEARCH (2012)
Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma - a single centre's experience
Mette O. Pedersen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Tina Marie Green et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Nathalie A. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The miR-17∼92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes
R. Bomben et al.
LEUKEMIA (2012)
Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP
Monica Testoni et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma
Matija Snuderl et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Jonathan W. Friedberg et al.
BLOOD (2010)
Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma
Christopher J. Stasik et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Rearrangement of MYC Is Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab
Sharon Barrans et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy
Kerry J. Savage et al.
BLOOD (2009)
Targeted deletion reveals essential and overlapping functions of the miR-17∼92 family of miRNA clusters
Andrea Ventura et al.
CELL (2008)
Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
W. Klapper et al.
LEUKEMIA (2008)
Stromal Gene Signatures in Large-B-Cell Lymphomas
G. Lenz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma
Linfeng Chen et al.
BLOOD (2008)
A microRNA polycistron as a potential human oncogene
L He et al.
NATURE (2005)
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response
S Monti et al.
BLOOD (2005)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
CP Hans et al.
BLOOD (2004)
Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma
A Ota et al.
CANCER RESEARCH (2004)
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
A Rosenwald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
Share Paper
